Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories

Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories

Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. Several independent studies suggest that higher non-synonymous mutational burden assessed by whole exome sequencing (WES) in tumors is associated with improved objective response...

Full description

Bibliographic Details
Main Authors: Ping Qiu, Ling Pang, Gladys Arreaza, Maureen Maguire, Ken C. N. Chang, Matthew J. Marton, Diane Levitan
Format: Article
Language:English
Published: MDPI AG 2016-04-01
Series:International Journal of Molecular Sciences
Subjects:
next generation sequencing (NGS)
whole exome sequencing (WES)
mutational burden
immune checkpoint inhibitor
PD-1
Online Access:http://www.mdpi.com/1422-0067/17/5/651

Internet

http://www.mdpi.com/1422-0067/17/5/651

Similar Items